Is Forte Biosciences Stock a Good Investment?
Forte Biosciences Investment Advice | FBRX |
- Examine Forte Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Forte Biosciences' leadership team and their track record. Good management can help Forte Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Forte Biosciences' business and its evolving consumer preferences.
- Compare Forte Biosciences' performance and market position to its competitors. Analyze how Forte Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Forte Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Forte Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Forte Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Forte Biosciences is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Actively responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Forte Biosciences Stock
Researching Forte Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 54.0% of the company shares are owned by institutional investors. The book value of Forte Biosciences was currently reported as 24.3. The company recorded a loss per share of 16.38. Forte Biosciences last dividend was issued on the 16th of June 2020. The entity had 1:25 split on the 28th of August 2024.
To determine if Forte Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Forte Biosciences' research are outlined below:
| Forte Biosciences is way too risky over 90 days horizon | |
| Forte Biosciences appears to be risky and price may revert if volatility continues | |
| Forte Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (31.48 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Forte Biosciences currently holds about 38.55 M in cash with (28.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.89. | |
| Forte Biosciences has a poor financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: Forte Biosciences Shares Are Soaring Today Whats Going On |
Forte Biosciences Quarterly Cash And Short Term Investments |
|
Forte Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Forte Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Forte Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Forte Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Forte Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-11-14 | 2022-09-30 | -0.15 | -0.18 | -0.03 | 20 | ||
2023-03-31 | 2022-12-31 | -0.16 | -0.23 | -0.07 | 43 | ||
2024-03-18 | 2023-12-31 | -0.28 | -0.19 | 0.09 | 32 | ||
2020-11-09 | 2020-09-30 | -0.54 | -0.45 | 0.09 | 16 | ||
2024-08-14 | 2024-06-30 | -0.17 | -0.27 | -0.1 | 58 | ||
2022-08-15 | 2022-06-30 | -0.32 | -0.21 | 0.11 | 34 | ||
2022-03-31 | 2021-12-31 | -0.32 | -0.21 | 0.11 | 34 | ||
2021-05-10 | 2021-03-31 | -0.52 | -0.36 | 0.16 | 30 |
Know Forte Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Forte Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Forte Biosciences backward and forwards among themselves. Forte Biosciences' institutional investor refers to the entity that pools money to purchase Forte Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-06-30 | 37.6 K | Susquehanna International Group, Llp | 2024-06-30 | 34.3 K | Vanguard Group Inc | 2024-09-30 | 26.4 K | Ubs Group Ag | 2024-06-30 | 24.3 K | Goldman Sachs Group Inc | 2024-06-30 | 20.8 K | Tower Research Capital Llc | 2024-06-30 | 15.8 K | Group One Trading, Lp | 2024-06-30 | 14 K | Hsbc Holdings Plc | 2024-06-30 | 10.7 K | Citadel Advisors Llc | 2024-06-30 | 8.1 K | Tybourne Capital Management (hk) Ltd | 2024-06-30 | 3.6 M | Cable Car Capital Llc | 2024-06-30 | 2 M |
Forte Biosciences' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.86 M.Market Cap |
|
Forte Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.81) | (0.85) | |
| Return On Capital Employed | (0.92) | (0.87) | |
| Return On Assets | (0.81) | (0.85) | |
| Return On Equity | (0.89) | (0.94) |
Determining Forte Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Forte Biosciences is a good buy. For example, gross profit margin measures Forte Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Forte Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Forte Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Forte Biosciences. Check Forte Biosciences' Beneish M Score to see the likelihood of Forte Biosciences' management manipulating its earnings.
Evaluate Forte Biosciences' management efficiency
Forte Biosciences has return on total asset (ROA) of (0.8125) % which means that it has lost $0.8125 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7091) %, meaning that it created substantial loss on money invested by shareholders. Forte Biosciences' management efficiency ratios could be used to measure how well Forte Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.85 in 2024. Return On Capital Employed is likely to rise to -0.87 in 2024. At this time, Forte Biosciences' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 831.9 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 620.4 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 27.96 | 26.57 | |
| Tangible Book Value Per Share | 27.96 | 26.57 | |
| Enterprise Value Over EBITDA | (0.43) | (0.45) | |
| Price Book Value Ratio | 0.73 | 0.70 | |
| Enterprise Value Multiple | (0.43) | (0.45) | |
| Price Fair Value | 0.73 | 0.70 | |
| Enterprise Value | 16.1 M | 15.3 M |
The strategic initiatives led by Forte Biosciences' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 1.455 |
Basic technical analysis of Forte Stock
As of the 22nd of November, Forte Biosciences shows the Downside Deviation of 4.17, mean deviation of 5.69, and Coefficient Of Variation of 937.32. Forte Biosciences technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Forte Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Forte Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Forte Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Forte Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Forte Biosciences' Outstanding Corporate Bonds
Forte Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Forte Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Forte bonds can be classified according to their maturity, which is the date when Forte Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| FORTUNE BRANDS HOME Corp BondUS34964CAA45 | View | |
| US34964CAE66 Corp BondUS34964CAE66 | View | |
| FBINUS 45 25 MAR 52 Corp BondUS34964CAG15 | View | |
| FBINUS 4 25 MAR 32 Corp BondUS34964CAF32 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US34960PAD33 Corp BondUS34960PAD33 | View | |
| FORTUNE BRANDS INC Corp BondUS349631AG67 | View |
Understand Forte Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Forte Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0909 | |||
| Market Risk Adjusted Performance | 1.01 | |||
| Mean Deviation | 5.69 | |||
| Semi Deviation | 3.43 | |||
| Downside Deviation | 4.17 | |||
| Coefficient Of Variation | 937.32 | |||
| Standard Deviation | 16.44 | |||
| Variance | 270.42 | |||
| Information Ratio | 0.1 | |||
| Jensen Alpha | 1.57 | |||
| Total Risk Alpha | (0.40) | |||
| Sortino Ratio | 0.3943 | |||
| Treynor Ratio | 1.0 | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (6.33) | |||
| Potential Upside | 6.65 | |||
| Downside Variance | 17.4 | |||
| Semi Variance | 11.76 | |||
| Expected Short fall | (8.77) | |||
| Skewness | 7.24 | |||
| Kurtosis | 56.43 |
| Risk Adjusted Performance | 0.0909 | |||
| Market Risk Adjusted Performance | 1.01 | |||
| Mean Deviation | 5.69 | |||
| Semi Deviation | 3.43 | |||
| Downside Deviation | 4.17 | |||
| Coefficient Of Variation | 937.32 | |||
| Standard Deviation | 16.44 | |||
| Variance | 270.42 | |||
| Information Ratio | 0.1 | |||
| Jensen Alpha | 1.57 | |||
| Total Risk Alpha | (0.40) | |||
| Sortino Ratio | 0.3943 | |||
| Treynor Ratio | 1.0 | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (6.33) | |||
| Potential Upside | 6.65 | |||
| Downside Variance | 17.4 | |||
| Semi Variance | 11.76 | |||
| Expected Short fall | (8.77) | |||
| Skewness | 7.24 | |||
| Kurtosis | 56.43 |
Consider Forte Biosciences' intraday indicators
Forte Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Forte Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Forte Biosciences Corporate Filings
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 2nd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 19th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Forte Stock media impact
Far too much social signal, news, headlines, and media speculation about Forte Biosciences that are available to investors today. That information is available publicly through Forte media outlets and privately through word of mouth or via Forte internal channels. However, regardless of the origin, that massive amount of Forte data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Forte Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Forte Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Forte Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Forte Biosciences alpha.
Forte Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Forte Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Additional Tools for Forte Stock Analysis
When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.